tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2021 Jun 3.
doi: 10.1111/irv.12871. Online ahead of print.
Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis
Brenda L Coleman[SUP] 1 2 3 [/SUP], Ruth Sanderson[SUP] 1 [/SUP], Mendel D M Haag[SUP] 4 [/SUP], Ian McGovern[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Standard-dose seasonal influenza vaccines often produce modest immunogenic responses in adults ≥65 years old. MF59 is intended to elicit a greater magnitude and increased breadth of immune response.
Objective: To determine the effectiveness of seasonal MF59-adjuvanted trivalent/quadrivalent influenza vaccine (aTIV/aQIV) relative to no vaccination or vaccination with standard or high-dose egg-based influenza vaccines among people ≥65 years old.
Methods: Cochrane methodological standards and PRISMA-P guidelines were followed. Real-world evidence from non-interventional studies published in peer-reviewed journals and gray literature from 1997 through to July 15, 2020, including cluster-randomized trials, were eligible. Two reviewers independently extracted data; risk of bias was assessed using the ROBINS-I tool.
Results: Twenty-one studies conducted during the 2006/07-2019/20 influenza seasons were included in the qualitative review; 16 in the meta-analyses. Meta-analysis of test-negative studies found that aTIV reduced medical encounters due to lab-confirmed influenza with pooled estimates of 40.7% (95% CI: 21.9, 54.9; I[SUP]2[/SUP] = 0%) for non-emergency outpatient visits and 58.5% (40.7, 70.9; I[SUP]2[/SUP] = 52.9%) for hospitalized patients. The pooled estimate of VE from case-control studies was 51.3% (39.1, 61.1; I[SUP]2[/SUP] = 0%) against influenza- or pneumonia-related hospitalization. The pooled estimates for the relative VE of aTIV for the prevention of influenza-related medical encounters were 13.9% (4.2, 23.5; I[SUP]2[/SUP] = 95.9%) compared with TIV, 13.7% (3.1, 24.2; I[SUP]2[/SUP] = 98.8%) compared with QIV, and 2.8% (-2.9, 8.5; I[SUP]2[/SUP] = 94.5%) compared with HD-TIV.
Conclusions: Among adults ≥65 years, aTIV demonstrated significant absolute VE, improved relative VE compared to non-adjuvanted standard-dose TIV/QIV, and comparable relative VE to high-dose TIV.
Keywords: MF59-adjuvanted influenza vaccine; older adults; real-world evidence; systematic literature review; vaccine effectiveness.
. 2021 Jun 3.
doi: 10.1111/irv.12871. Online ahead of print.
Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis
Brenda L Coleman[SUP] 1 2 3 [/SUP], Ruth Sanderson[SUP] 1 [/SUP], Mendel D M Haag[SUP] 4 [/SUP], Ian McGovern[SUP] 5 [/SUP]
Affiliations
- PMID: 34081398
- DOI: 10.1111/irv.12871
Abstract
Background: Standard-dose seasonal influenza vaccines often produce modest immunogenic responses in adults ≥65 years old. MF59 is intended to elicit a greater magnitude and increased breadth of immune response.
Objective: To determine the effectiveness of seasonal MF59-adjuvanted trivalent/quadrivalent influenza vaccine (aTIV/aQIV) relative to no vaccination or vaccination with standard or high-dose egg-based influenza vaccines among people ≥65 years old.
Methods: Cochrane methodological standards and PRISMA-P guidelines were followed. Real-world evidence from non-interventional studies published in peer-reviewed journals and gray literature from 1997 through to July 15, 2020, including cluster-randomized trials, were eligible. Two reviewers independently extracted data; risk of bias was assessed using the ROBINS-I tool.
Results: Twenty-one studies conducted during the 2006/07-2019/20 influenza seasons were included in the qualitative review; 16 in the meta-analyses. Meta-analysis of test-negative studies found that aTIV reduced medical encounters due to lab-confirmed influenza with pooled estimates of 40.7% (95% CI: 21.9, 54.9; I[SUP]2[/SUP] = 0%) for non-emergency outpatient visits and 58.5% (40.7, 70.9; I[SUP]2[/SUP] = 52.9%) for hospitalized patients. The pooled estimate of VE from case-control studies was 51.3% (39.1, 61.1; I[SUP]2[/SUP] = 0%) against influenza- or pneumonia-related hospitalization. The pooled estimates for the relative VE of aTIV for the prevention of influenza-related medical encounters were 13.9% (4.2, 23.5; I[SUP]2[/SUP] = 95.9%) compared with TIV, 13.7% (3.1, 24.2; I[SUP]2[/SUP] = 98.8%) compared with QIV, and 2.8% (-2.9, 8.5; I[SUP]2[/SUP] = 94.5%) compared with HD-TIV.
Conclusions: Among adults ≥65 years, aTIV demonstrated significant absolute VE, improved relative VE compared to non-adjuvanted standard-dose TIV/QIV, and comparable relative VE to high-dose TIV.
Keywords: MF59-adjuvanted influenza vaccine; older adults; real-world evidence; systematic literature review; vaccine effectiveness.